SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Carbylan Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Carbylan Therapeutics, Inc. ("Carbylan" or the "Company") CBYL concerning possible violations of federal securities laws by certain officers and directors.

On April 9, 2015, Carbylan's stock traded as high as $6.58, the same day the Company sold 13 million shares of stock in its initial public stock offering, raising $65.0 million in new capital. Since the IPO, however, Carbylan's stock has fallen from its high of $9.22 on June 8, 2015 to close at $0.71 on March 15, 2016. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/carbylan-therapeutics

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160322006405/en/